The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs
Open accessAbstract
This review illustrates notable recent progress in the field of medicinal bioinorganic chemistry with many new approaches to the design of innovative metal-based anticancer drugs emerging. Current research addressing the problems associated with platinum drugs has focused on other metal-based therapeutics that have different modes of action, and on prodrug and targeting strategies in an effort to diminish the side-effects of cisplatin chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Current Clinical and Preclinical Photosensitizers for Use in Photodynamic Therapy
Detty, M. R., Gibson, S. L., & Wagner, S. J. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040074b · Cited by 1,045
Shaw, C. F. (1999) · Chemical Reviews · doi:10.1021/cr980431o · Cited by 990
Photodynamic therapeutics: basic principles and clinical applications
Sharman, W. M., Allen, C. M., & van Lier, J. E. (1999) · Drug Discovery Today · doi:10.1016/s1359-6446(99)01412-9 · Cited by 925
Non-Platinum Chemotherapeutic Metallopharmaceuticals
Clarke, M. J., Zhu, F., & Frasca, D. R. (1999) · Chemical Reviews · doi:10.1021/cr9804238 · Cited by 908
Guo, Z., & Sadler, P. J. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19990601)38:11<1512::aid-anie1512>3.0.co;2-y · Cited by 834
Self-citationRademaker-Lakhai, J. M., van den Bongard, D., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0746 · Cited by 833
Feazell, R. P., Nakayama-Ratchford, N., Dai, H., & Lippard, S. J. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073231f · Cited by 616
Non Platinum Metal Complexes as Anti‐cancer Drugs
Ott, I., & Gust, R. (2007) · Archiv der Pharmazie · doi:10.1002/ardp.200600151 · Cited by 609
Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs
Bindoli, A., Rigobello, M. P., Scutari, G., Gabbiani, C., Casini, A., & Messori, L. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.026 · Cited by 595
Aird, R. E., Cummings, J., Ritchie, A. A., Muir, M., Morris, R. E., Chen, H., Sadler, P. J., & Jodrell, D. I. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600290 · Cited by 582
Self-citationBiological inorganic chemistry: structure and reactivity
(2007) · Choice Reviews Online · doi:10.5860/choice.44-6242 · Cited by 573
Basis for Design and Development of Platinum(IV) Anticancer Complexes
Hall, M. D., Mellor, H. R., Callaghan, R., & Hambley, T. W. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070280u · Cited by 458
Targeting the mitochondrial cell death pathway with gold compounds
Barnard, P. J., & Berners-Price, S. J. (2007) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2007.04.006 · Cited by 417
Metal based drugs: from serendipity to design
Fricker, S. P. (2007) · Dalton Transactions · doi:10.1039/b705551j · Cited by 414
Metals and metal compounds in cancer treatment.
Desoize, B. (2004) · PubMed · Cited by 349
Design of targeting ligands in medicinal inorganic chemistry
Storr, T., Thompson, K. H., & Orvig, C. (2006) · Chemical Society Reviews · doi:10.1039/b514859f · Cited by 326
Ang, W. H., Khalaila, I., Allardyce, C. S., Juillerat-Jeanneret, L., & Dyson, P. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0432618 · Cited by 314
Catalytic organometallic anticancer complexes
Dougan, S. J., Habtemariam, A., McHale, S. E., Parsons, S., & Sadler, P. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800076105 · Cited by 303 · cited 1×
“Interestingly, the redox cycle involves the oxidation of the strong reducing agent glutathione present in millimolar concentrations, in the presence of micromolar concentrations of the ruthenium complex [66].”
BackgroundSelf-citationA potent cytotoxic photoactivated platinum complex
Mackay, F. S., Woods, J. A., Heringová, P., Kašpárková, J., Pizarro, A. M., Moggach, S. A., Parsons, S., Brabec, V., & Sadler, P. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707742105 · Cited by 303
Self-citationRuthenium complexes can target determinants of tumour malignancy
Bergamo, A., & Sava, G. (2007) · Dalton Transactions · doi:10.1039/b617769g · Cited by 291
Thioredoxin signaling as a target for cancer therapy
Powis, G., & Kirkpatrick, D. L. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.04.003 · Cited by 264
Barnes, K. R., Kutikov, A., & Lippard, S. J. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.024 · Cited by 263
Chatterjee, S., Kundu, S., Bhattacharyya, A., Hartinger, C. G., & Dyson, P. J. (2008) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-008-0400-9 · Cited by 258
Wang, F., Chen, H., Parsons, S., Oswald, I. D. H., Davidson, J. E., & Sadler, P. J. (2003) · Chemistry – A European Journal · doi:10.1002/chem.200304724 · Cited by 254
Self-citationSmalley, K. S. M., Contractor, R., Haass, N. K., Kulp, A. N., Atilla-Gokcumen, G. E., Williams, D. S., Bregman, H., Flaherty, K. T., Soengas, M. S., Meggers, E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1538 · Cited by 230
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
Choy, H., Park, C., & Yao, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2176 · Cited by 217
Ott, I., Schmidt, K., Kircher, B., Schumacher, P., Wiglenda, T., & Gust, R. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049326z · Cited by 207
Vessières, A., Top, S., Pigeon, P., Hillard, E., Boubeker, L., Spera, D., & Jaouen, G. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050251o · Cited by 206
Undressing of Phosphine Gold( I ) Complexes as Irreversible Inhibitors of Human Disulfide Reductases
Urig, S., Fritz‐Wolf, K., Réau, R., Herold‐Mende, C., Tóth, K., Davioud‐Charvet, E., & Becker, K. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502756 · Cited by 206
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound
Bergamo (1992) · International Journal of Oncology · doi:10.3892/ijo_00000119 · Cited by 202
Failes, T. W., Cullinane, C. M., Diakos, C. I., Yamamoto, N., Lyons, J. G., & Hambley, T. W. (2006) · Chemistry - A European Journal · doi:10.1002/chem.200601137 · Cited by 143
Campone, M., Rademaker-Lakhai, J. M., Bennouna, J., Howell, S. B., Nowotnik, D. P., Beijnen, J. H., & Schellens, J. H. M. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0397-0 · Cited by 125
Induced-fit recognition of DNA by organometallic complexes with dynamic stereogenic centers
Chen, H., Parkinson, J. A., Nováková, O., Bella, J., Wang, F., Dawson, A., Gould, R. O., Parsons, S., Brabec, V., & Sadler, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2434016100 · Cited by 125
Self-citationOrganometallic Osmium(II) Arene Anticancer Complexes Containing Picolinate Derivatives
van Rijt, S., Peacock, A. F. A., Johnstone, R. D. L., Parsons, S., & Sadler, P. J. (2009) · Inorganic Chemistry · doi:10.1021/ic8020222 · Cited by 112
Self-citationGabbiani, C., Casini, A., Luigi Messori, A., Guerri, A., Cinellu, M. A., Minghetti, G., Corsini, M., Rosani, C., Zanello, P., & Arca, M. (2008) · Inorganic Chemistry · doi:10.1021/ic701254s · Cited by 105
A rhodium(III) complex for high-affinity DNA base-pair mismatch recognition
Junicke, H., Hart, J. R., Kisko, J. L., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0537194100 · Cited by 88
Sessler, J. L., Doctrow, S. R., McMurry3, T. J., & Lippard, S. J. (2005) · ACS symposium series · doi:10.1021/bk-2005-0903 · Cited by 80
Oxidation induced by the antioxidant glutathione (GSH)
Petzold, H., & Sadler, P. J. (2008) · Chemical Communications · doi:10.1039/b805358h · Cited by 43
Self-citationPre-clinical antitumour evaluation of Biphosphinic Palladacycle Complex in human leukaemia cells
Oliveira, C. R., Barbosa, C. M. V., Nascimento, F. D., Lanetzki, C. S., Meneghin, M. B. L., Pereira, F. E. G., Paredes‐Gamero, E. J., Ferreira, A. T., Rodrigues, T., Queiroz, M. L. S., et al. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.10.034 · Cited by 31
Cited by
Nanoparticles for photothermal therapies
Jaque, D., Martínez Maestro, L., del Rosal, B., Haro-Gonzalez, P., Benayas, A., Plaza, J. L., Martín Rodríguez, E., & García Solé, J. (2014) · Nanoscale · doi:10.1039/c4nr00708e · Cited by 1,936
Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs
Liu, W., & Gust, R. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35314h · Cited by 762
Stimuli-Responsive Therapeutic Metallodrugs
Wang, X., Wang, X., Jin, S., Muhammad, N., & Guo, Z. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 649
Tackling the Challenges of Enzymatic (Bio)Fuel Cells
Xiao, X., Xia, H.-Q., Wu, R., Bai, L., Yan, L., Magner, E., Cosnier, S., Lojou, E., Zhu, Z., & Liu, A. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00115 · Cited by 504
Binding of transition metal ions to albumin: Sites, affinities and rates
Bal, W., Sokołowska, M., Kurowska, E., & Faller, P. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.06.018 · Cited by 489
Metadata
- Authors
- van Rijt, S. H., & Sadler, P. J.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2009-12
- Volume
- 14
- Issue
- 23-24
- Pages
- 1089-1097
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2112891180
- Cited by
- 592
- References
- 41
- FWCI
- 15.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.